Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any thrombocytopenia in which the cause of the disease is a mutation in the CYCS gene.
Features include always present findings: Low platelet count (thrombocytopenia). 2 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Blood and immune system | 2 | Abnormal platelet volume, Low platelet count (thrombocytopenia) |
CYCS encodes cytochrome c, somatic (105 aa). Electron carrier protein. The oxidized form of the cytochrome c heme group can accept an electron from the heme group of the cytochrome c1 subunit of cytochrome reductase. Highest expression in Heart Atrial Appendage (131.9 TPM) and Heart Left Ventricle (123.8 TPM).
Thrombocytopenia 4 has limited evidence linking it to mutations in the CYCS gene on chromosome 7.
The CYCS protein participates in Cytochrome c (reduced), Cytochrome c (oxidised), and Expression of CYCS pathways.
CYCS is classified as a druggable target with score 0.0.
Genetic testing for CYCS is available. Testing is considered research-grade for diagnosis.
Biomarker and diagnostic research for thrombocytopenia 4 has been reported in the published literature.
Phenotype severity distribution: 1 always present feature.
1 clinical trial registered. Interventions under study include procedural interventions. Research is primarily sponsored by academic and government institutions.
155 publications have been identified in PubMed for thrombocytopenia 4. Research spans Clinical Trial Publication (23%), Basic Science / Preclinical (23%), and Epidemiology / Natural History (17%).
Research Type | Count | % of Total |
|---|---|---|
Clinical study results | 36 | 23% |
Data assembled from 7 of 12 sources · Last updated Sep 18, 2026, 5:34 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Laboratory research |
36 |
23% |
Disease patterns and progression | 27 | 17% |
Patient case studies | 22 | 14% |
Research summaries | 19 | 12% |
Testing and diagnosis research | 9 | 6% |
New treatment approaches | 4 | 3% |
Other research | 2 | 1% |
Khanolkar L (2026). [PMID: 41818131](https://pubmed.ncbi.nlm.nih.gov/41818131/). *Radiographics*. [Review / Meta-Analysis]
Rich B (2026). [PMID: 41055137](https://pubmed.ncbi.nlm.nih.gov/41055137/). *Clin Pharmacol Ther*. [Basic Science / Preclinical]
Jiang S (2026). [PMID: 40820810](https://pubmed.ncbi.nlm.nih.gov/40820810/). *Haematologica*. [Basic Science / Preclinical]
Chen X (2026). [PMID: 41365333](https://pubmed.ncbi.nlm.nih.gov/41365333/). *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. [Clinical Trial Publication]
Rousseau Z (2026). [PMID: 42055323](https://pubmed.ncbi.nlm.nih.gov/42055323/). *J Biol Chem*. [Basic Science / Preclinical]
Ruan J (2026). [PMID: 41289154](https://pubmed.ncbi.nlm.nih.gov/41289154/). *Blood advances*. [Case Report / Case Series]
Chinnam D (2026). [PMID: 42142282](https://pubmed.ncbi.nlm.nih.gov/42142282/). *J Hematop*. [Epidemiology / Natural History]
Martinelli G (2026). [PMID: 41536779](https://pubmed.ncbi.nlm.nih.gov/41536779/). *Blood neoplasia*. [Basic Science / Preclinical]
Hai L (2026). [PMID: 40235276](https://pubmed.ncbi.nlm.nih.gov/40235276/). *British journal of haematology*. [Basic Science / Preclinical]
Smith MA (2026). [PMID: 41248753](https://pubmed.ncbi.nlm.nih.gov/41248753/). *Transplant Cell Ther*. [Diagnostic / Biomarker]